DSM Personal Care has announced the transfer of the manufacturing process of its SYNPeptides portfolio from DSM’s multipurpose plant in Aesch, Switzerland to its larger manufacturing facility at Village-Neuf (France).
Last year SYN-AKE and SYN-HYCAN peptides were listed in the Inventory of Existing Cosmetic Ingredients in China (IECIC), alongside the SYN-COLL peptide indexed earlier. This decision makes the portfolio even more attractive for personal care players focusing on a fast-growing Chinese market. New scientific data and applications tailored to specific customer needs have significantly expanded the demand for these actives.
The transition is expected to be completed in the course of 2015. The larger capacities of the Village-Neuf site make it possible to scale up production of new and existing peptides while maintaining service quality.
Wilfrid Gambade, president DSM Personal Care, commented: “This is a significant step towards achieving our growth ambitions. Peptide competence for the personal care is instrumental in developing breakthrough innovation for customised and also global solutions. Our R&D investments into this key technology along with our activities on the supply chain will help fuel the growth of our skin care business.”
